about
Amantadine for fatigue in multiple sclerosisN-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's diseaseAmantadine for dyskinesias in Parkinson's disease: a randomized controlled trialGlutamate receptor ion channels: structure, regulation, and functionAmantadine and cognitive flexibility: decision making in Parkinson's patients with severe pathological gambling and other impulse control disorders.Medication-Induced Tardive Dyskinesia: A Review and Update.The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivativesLong term motor complications of levodopa: clinical features, mechanisms, and management strategies.Clinical aspects and management of levodopa-induced dyskinesia.An updated meta-analysis of amantadine for treating dyskinesia in Parkinson's disease.α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage.NMDA receptors in clinical neurology: excitatory times ahead.Systems-level neurophysiological state characteristics for drug evaluation in an animal model of levodopa-induced dyskinesia.Optogenetic activation of striatal cholinergic interneurons regulates L-dopa-induced dyskinesiasTrends in antiparkinsonian medication use in new zealand: 1995-2011.Drug therapy in patients with Parkinson's disease.Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease.
P2860
Q24246259-ED9B6D3C-3A52-459E-9044-7009509BB22DQ26825619-13EF8FEF-9632-44BA-ADDA-5D110B3FB9D3Q27312728-F7A97EAA-3403-4ADA-8CC7-418E04B3EA33Q28290774-713F79C8-1CEF-4505-BA7D-7602267F19A8Q33800742-E5BAA33F-02EC-4EFD-8CDA-8D38123910B1Q33802645-FA9E3C8D-0266-4248-8D73-9251EDAB6967Q34329204-C44EE40B-C0CF-4A7E-B0D7-2E6B9FC3F42FQ35858048-518C47FB-B50E-4AD4-8A2B-C81D38CF5589Q36022700-378711D1-7D31-4888-A232-F60CC60B9DACQ36376607-DED96A70-6ACB-4AB1-9020-8726F2B4E3E6Q36469995-D3EDEAB5-EF93-40D8-8FB3-4EEE41E9C1F4Q36660216-79101B35-7E3A-4E66-845F-A20ABCB08FCDQ36735012-4F280CD5-E25C-4708-932A-E29FA8FDD955Q36880148-76713BD6-1B12-4D58-81BD-1EAFB04F9E77Q37651160-63330038-9DBC-438D-A26C-86F609479C90Q38064971-7B6FBF2E-5C1C-4D6A-98E1-31703070B1E7Q46641045-DBDDD363-7CC3-4748-AF53-A1E34DDC3AF3Q52658932-39D4F4CB-FF41-40FD-9F60-EED1A0D9AD5E
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Amantadine for dyskinesia in Parkinson's disease
@ast
Amantadine for dyskinesia in Parkinson's disease
@en
Amantadine for dyskinesia in Parkinson's disease
@en-gb
Amantadine for dyskinesia in Parkinson's disease
@nl
type
label
Amantadine for dyskinesia in Parkinson's disease
@ast
Amantadine for dyskinesia in Parkinson's disease
@en
Amantadine for dyskinesia in Parkinson's disease
@en-gb
Amantadine for dyskinesia in Parkinson's disease
@nl
prefLabel
Amantadine for dyskinesia in Parkinson's disease
@ast
Amantadine for dyskinesia in Parkinson's disease
@en
Amantadine for dyskinesia in Parkinson's disease
@en-gb
Amantadine for dyskinesia in Parkinson's disease
@nl
P2860
P50
P1476
Amantadine for dyskinesia in Parkinson's disease
@en
P2093
Carl E Clarke
P2860
P304
P356
10.1002/14651858.CD003467
P577
2003-01-01T00:00:00Z